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(57) ABSTRACT 
The invention relates to aequorin and obelin mutants Whose 
emission is shifted With respect to Wild type. The shift in 
emission is accomplished using a combination of mutations 
of amino acids Within aequorin or obelin that affect biolu 
minescence; use of different types of chromophores, i.e., 
coelenteraZines with variable emission characteristics; and 
modi?cations of the photoprotein with ?uorophores that Will 
allow for emission of light at longer Wavelengths as a result 
of energy transfer. Additionally, an assay employing 
aequorin mutants to test for HIV-1 protease inhibitors is 
disclosed. 
2 Claims, 18 Drawing Sheets 
a table showing the emission wavelength maximum (nm) of aequorin mutants 
with coelenterazine analogues. 
Coelenterazine Wild Type Aequorin Aequorin Aequorin 
Analogue Aequorin Mutant S Mutant S Mutant S 
(Aeq3) SerSCys (Aeq5) Tyrl321le 
CTZ i 472 491 491 487 
CTZ ip 472 470 454 453 
CTZ h 472 476 471 471 
CTZ hep 472 476 448 465 
CTZ cp 472 470 456 457 
CTZ fcp 472 466 471 471 
CTZ f 472 490 473 471 
CTZ n 472 487 
CTZ native 472 474 471 471 
* All values, except wild type aequorin, were calculated from the average of 3 trials (wild 
type with 2). All mutants were, except Aeq5 puri?ed to >95% purity. CTZ analogues 
diluted to 100 micrograms/n11 methanol. 
US 7,345,160 B2 
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Fig. 1 
Fig. 1 is a table showing the emission wavelength maximum (nm) of aequorin mutants 
with coelenterazine analogues. 
Coelenterazine Wild Type Aequorin Aequorin Aequorin 
Analogue Aequorin Mutant S Mutant S Mutant S 
(Aeq3) SerS Cys (Aeq5) Tyrl 32I1e 
CTZ i 472 491 491 487 
CTZ ip 472 470 454 453 
CTZ h 472 476 471 471 
CTZ hep 472 476 448 465 
CTZ cp 472 470 456 457 
CTZ fcp 472 466 471 471 
CTZ f 472 490 473 471 
CTZ n 472 487 
CTZ native 472 474 471 471 
* All values, except wild type aequorin, were calculated from the average of 3 trials (wild 
type with 2). All mutants were, except Aeq5 puri?ed to >95% purity. CTZ analogues 
diluted to 100 micrograms/ml methanol. 
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Fig. 7 
Fig. 7 is a table showing the emission wavelength maximum (nm) of aequorin mutant 
Mutant S Y132l, Mutant S having a 3-fluoro-1-tyrosine aequorin or a 5-fluoro-1-tyrosine 
non-natural amino acid in position 132 in conjunction with coelenterazine analogues CTZ 
i, ip, n, h, hcp, cp, fcp, f and native CTZ. 
Coelenterazine Wild Type Aequorin Aequorin Aequorin 
Analogue Aequorin Mutant S Mutant S Mutant S 
Tyr1321le Tyr132 Tyr132 
3-?u0r0-l-tyr S-?uoro-l-trp 
CTZ i 472 491 51 1 495 
CTZ ip 472 452 471 
CTZ n 472 ' 491 500 
CTZ h 472 472 498 471 
CTZ hcp 472 452 471 468 
CTZ cp 472 457 471 471 
CTZ fcp 472 463 471 
CTZ f 472 472 500 497 
CTZ native 472 471 495 472 
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Fig. 11 
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SEQ ID NO: 1 cDNA encoding wild type apoaequorin 
1 aatgcaattc atctttgcat caaagaatta catcaaatct 
ctagttgatc aactaaattg 
61 tctcgacaac aacaagcaaa 
cagtcaagct tacatcagac 
121 ttcgacaacc caagatggat 
tcaatttcct tgatgtcaac 
181 cacaatggaa aaat'ctctct 
catctgatat tgtcatcaat 
241 aaccttggag caacacctga 
atgctgtaga agccttcttc 
301 ggaggagctg gaatgaaata 
ctgcatatat tgaaggatgg 
361 aaaaaattgg ctactgatga 
acgaaccaac gctcatccgt 
421 atatggggtg atgctttgtt 
aaaatggagc cattacactg 
481 gatgaatgga aagcatacac 
aatcatcaga agattgcgag 
541 gaaacattca gagtgtgcga 
tcgatgttga tgagatgaca 
601 agacaacatt taggattttg 
gcgaaaagct ctacggtgga 
661 gctgtcccct aagaagctct 
gaagatgatg tgattttgaa 
721 taaaacactg atgaattcaa 
gaacgatttc aatcgtttgt 
781 gttgattttt gtaattagga 
agttgttttt ttaatcaaca 




























SEQID NO: 2 amino acid‘ sequence for wild type apoaequorin 
VKLTSDFDNP RWIGRHKHMF NFLDVNHNGK ISLDEMVYKA SDIVINNLGA 
TPEQAKRHKD AVEAFFGGAG MKYGVETDWP AYIEGWKKLA TDELEKYAKN 
EPTLIRIWGD ALFDIVDKDQ NGAITLDEWK AYTKAAGIIQ SSEDCEETFR 
VCDIDESGQL DVDEMTRQHL GFWYTMDPAC EKLYGGAVP 
U.S. Patent Mar. 18,2008 
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SEQ ID NO: 3 cDNA encoding 
1 aatgcaattc atctttgcat 
ctagttgatc aactaaattg 
61 tctcgacaac aacaagcaaa 
cagtcaagct tacatcagac 
121 ttcgacaacc caagatggat 
tcaatttcct tgatgtcaac 
181 ca'caatggaa aaatctctct 
catctgatat tgtcatcaat ' 
241 aaccttggag caacacctga 
atgctgtaga agccttcttc 
301 ggaggagctg gaatgaaata 
ctgcatatat tgaaggatgg 
361 aaaaaattgg ctactgatga 
acgaaccaac gctcatccgt 
421 atatggggtg atgctttgtt 
aaaatggagc cattacactg 
481 gatgaatgga aagcatacac 
aatcatcaga agatagcgag 
541 gaaacattca gagtgagcga 
tcgatgttga tgagatgaca 
601 agacaacatt taggattttg 
gcgaaaagct Ctacggtgga 
661 gctgtcccct aagaagctct 
gaagatgatg tgattttgaa 
721 taaaacactg atgaattcaa 
gaacgatttc aatcgtttg't 
781 gttgattttt gtaattagga 
agttgttttt ttaatcaaca 
841 gaact-tacaa atcgaaaaag 
Fig. 14 
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SEQ |D.NO: 4 amino acid sequence for "Mutant S" apoaequorin 
VKLTSDFDNP RWIGRHKHMF NFLDVNHNGK ISLDEMVYKA SDIVINNLGA 
TPEQAKRHKD AVEAFFGGAG MKYGVETDWP AYIEGWKKLA TDELEKYAKN 
EPTLIRIWGD ALFDIVDKDQ NGAITLDEWK AYTKAAGIIQ SSEDSEETFR 
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Non-natural amino acids 
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Non-natural Amino 
Acid Analogue 
Representative Example Effect 
Fluoro-analogue .n g o O I 
H O NH: 
3-?uoro-L-tyrosine 
Altered pKa and H 
bonding strength 
Amine-analogue OH 553 H=~ N 
p-amino-L-phenylalanine 
Altered electrostatic 
charge and H 
bonding strength 











pKa, altered H 
bonding strength, 






Altered pKa, loss of 
n-n interactions 
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Fig. 18 SEQ ID NO: 5, Obelin cDNA sequence 
1 acgatcgaac caaacaactc agctcacagc tactgaacaa 
ctcttgttgt gtacaatcaa 
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Fig. 19. SEQ ID NO: 6, Native Obelin Amino Acid 
Sequence 
MSSKYAVKLK TDFDNPRWIK RHKHMFDFLD INGNGKITLD EIVSKASDDI 
CAKLEATPEQ TKRHQVCVEA FFRGCGMEYG KEIAFPQFLD GWKQLATSEL 
KKWARNEPTL IREWGDAVFD IFDKDGSGTI TLDEWKAYGK ISGISPSQED 
CEATFRHCDL DNSGDLDVDE MTRQHLGFWY TLDPEADGLY GNGVP 
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Fig. 20 Obelin mutants with Coelenerazine analogues. 
Coelenterazine Analogs Emission Max (nm) 
Obelin i ip h hcp cp fcp f ctz 
Mutant 
C75 8- 521 478 503 478 472 497 503 491 
C51 S 
C75S- 505 471 500 471 471 487 504 491 
G678 
C1588 506 472 497 478 472 475 497 491 
C1-51S 497 471 490 471 471 474 493 491 












